BioForce Announces the First International Order for a NanoArrayer™ System
News Jan 30, 2006
BioForce Nanosciences has announced receipt of the first international order for a NanoArrayer System.
The order was placed by the Institute of Biomedical Chemistry, a division of the Russian Academy of Medical Sciences in Moscow, Russia.
Several laboratories within the Proteomics Research department have projects that will benefit from the biomolecular printing capabilities the NanoArrayer System offers.
The primary researcher will be Dr. Yuri Ivanov, head of the Nanobiotechnology group, who will focus on using the NanoArrayer to immobilize proteins and peptides on Sindex™ chips for nanoscale detection and analysis.
Michael Lynch, NanoArrayer System Product Manager, was the primary contact responsible for completing this sales agreement with the IBMC.
"One of the key accomplishments last year was the completion of several formal distribution agreements covering territories including Japan, China, Korea and Europe," Michael observed.
"We view the international promotion, sales and support of the NanoArrayer System as a fundamental part of the Sales and Marketing process and important to the success of this new product line. We look forward to working with Dr. Ivanov in supporting his research."
"As an innovative technology company, BioForce envisions providing enabling technology such as the NanoArrayer System to academic and corporate researchers throughout the world," noted Dr. Eric Henderson, Founder and CEO of BioForce Nanosciences.
"We have been very proactive in protecting the technology-associated intellectual property through the U.S. and international patent process to meet this vision and protect the value for our shareholders."
"With the placement of the first international order for a NanoArrayer System we have achieved a significant milestone in the evolution of our company."
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.
Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of BloodNews
A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.READ MORE